1. Exacerbation of Previously Undiagnosed Bird Fancier’s Lung by Pembrolizumab Therapy 
Ann Vu, MD, Robert Vassallo, MD, Jay H. Ryu, MD 
CHEST 
Volume 155, Issue 4, Pages e79-e82 (April 2019)
DOI: /j.chest
Copyright © 2018 American College of Chest Physicians Terms and Conditions

2. Figure 1
A, Chest CT angiography 5½ weeks following initiation of pembrolizumab therapy demonstrating bilateral ground-glass and reticular opacities with an underlying mosaic attenuation pattern. B, CT imaging obtained 4 weeks before the start of pembrolizumab therapy demonstrating preexisting mild ground-glass and reticular opacities bilaterally with an underlying mosaic attenuation pattern.
CHEST  , e79-e82DOI: ( /j.chest )
Copyright © 2018 American College of Chest Physicians Terms and Conditions

3. Figure 2
A, Chest radiographic imaging prior to the start of steroid therapy for Bird fancier’s lung exacerbated by pembrolizumab therapy. B, Follow-up chest radiographic imaging at 3 months after the diagnosis of Bird fancier’s lung.
CHEST  , e79-e82DOI: ( /j.chest )
Copyright © 2018 American College of Chest Physicians Terms and Conditions